Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | LDHB | P07195 | 1/20 | 0.45 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13185222 | 0.97 | ALDH1A1 (0.57) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL396870 | 0.84 | ALDH1A1 (0.80) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL5484625 | 0.80 | MMP3 (0.50) | ALDH1A1TNKSKCNH2SCN10AAR | |
| SCHEMBL14450253 | 0.80 | ALDH1A1 (0.56) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL3503161 | 0.78 | MMP3 (0.48) | ALDH1A1TNKSKCNH2SCN10AAR | |
| SCHEMBL11608803 | 0.78 | SMN1; SMN2 (0.63) | KDM4EALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL11608800 | 0.78 | SMN1; SMN2 (0.63) | KDM4EALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL12177745 | 0.77 | ALDH1A1 (0.69) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL13681302 | 0.76 | ALDH1A1 (0.40) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL398700 | 0.76 | ALDH1A1 (0.67) | KDM4EALDH1A1LMNATDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119330967-B | MET transcription inhibitor and preparation method and application thereof | 中国药科大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-119330967-A | MET transcription inhibitor and preparation method and application thereof | 中国药科大学 | 2025-01-21 | — | — | CN | disclosed |
| US-11572351-B1 | Bis-Schiff base compositions and formulations | Systima Technologies, Inc. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11028194-B1 | Bis-Schiff base compositions and formulations | Jalapeno Holdings, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-8466291-B2 | 1,5-dideoxy-1,5-imino-D-glucitol compounds | ACADEMIA SINICA (TW) | 2013-06-18 | — | — | US | disclosed |
| US-8466291-B2 | 1,5-dideoxy-1,5-imino-D-glucitol compounds | ACADEMIA SINICA (TW) | 2013-06-18 | — | — | US | disclosed |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | ACADEMIA SINICA (TW) | 2010-05-06 | — | — | US | disclosed |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | ACADEMIA SINICA (TW) | 2010-05-06 | — | — | US | disclosed |
| EP-1830848-B1 | USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS | CELL THERAPEUTICS EUROPE SRL (IT) | 2009-12-16 | — | — | EP | disclosed |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7183286-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-02-27 | — | — | US | disclosed |
| US-7163955-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070010533-A1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-11 | — | — | US | disclosed |
| WO-2006066846-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
| US-20060063931-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-23 | — | — | US | disclosed |
| EP-1399163-A2 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20030199521-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-23 | — | — | US | disclosed |
| WO-2002055025-A2 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | UNIV NORTH CAROLINA (US) | 2002-07-18 | — | — | WO | disclosed |
| US-4070380-A | 5-(4-Amidinophenyl)-2-furamidine dihydrochloride monohydrate | MORTON-NORWICH PRODUCTS, INC. (US) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199521-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | KDM4E 4251/4885ALDH1A1 493/4885LMNA 1825/4885 |
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | PLD2, PLD1, PLA2G2D | KDM4E 2591/4885ALDH1A1 1070/4885LMNA 2840/4885 |
| US-11028194-B1 | Bis-Schiff base compositions and formulations | FHIT, H1-0, H1-2 | KDM4E 3246/4885ALDH1A1 859/4885LMNA 368/4885 |
| US-20060063931-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | KDM4E 4251/4885ALDH1A1 493/4885LMNA 1825/4885 |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | EP300, HIF1A, HIF1AN | KDM4E 1039/4885ALDH1A1 65/4885LMNA 2151/4885 |
| US-11572351-B1 | Bis-Schiff base compositions and formulations | FHIT, H1-0, H1-2 | KDM4E 3184/4885ALDH1A1 785/4885LMNA 389/4885 |
| US-20070010533-A1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | OAT, GYS2, HCCS | KDM4E 4251/4885ALDH1A1 493/4885LMNA 1825/4885 |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | HEXD, GALE, GBA1 | KDM4E 3356/4885ALDH1A1 321/4885LMNA 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.